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Background: Re-testing for GH secretion is needed to confirm the diagnosis of GH
deficiency (GHD) after adult height achievement in childhood-onset GHD (COGHD).
Aim: To define the cut-off of GH peak after retesting with GH-releasing hormone plus
arginine (GHRHarg) in the diagnosis of permanent GHD in COGHD of different etiology.
Patients and methods: Eighty-eight COGHD (median age 17.2 y), 29 idiopathic GHD
(IGHD), 44 cancer survivors (TGHD) and 15 congenital GHD (CGHD) were enrolled in the
study; 54 had isolated GHD (iGHD) and 34 had multiple pituitary hormone deficiencies
(MPHD). All were tested with insulin tolerance test (ITT) and GHRHarg. IGHD with a GH
response to ITT≥6µg/L were considered true negatives and served as the control group,
and patients with a GH response <6µg/L as true positives. Baseline IGF-I was also
measured. The diagnostic accuracy of GHRHarg testing and of IGF-I SDS in patients
with GHD of different etiologies was evaluated by ROC analysis.
Results: Forty-six subjects with a GH peak to ITT ≥6µg/L and 42 with GH peak <6
µg/L showed a GH peak after GHRHarg between 8.8–124µg/L and 0.3–26.3µg/L,
respectively; 29 IGHD were true negatives, 42 were true positives and 17 with a high
likelihood GHD showed a GH peak to ITT ≥6µg/L. ROC analysis based on the etiology
indicated the best diagnostic accuracy for peak GH cutoffs after GHRHarg of 25.3 µg/L
Patti et al. GHRHarg Retesting in Transition Age
in CGHD, 15.7 in TGHD, and 13.8 in MPHD, and for IGF-1 SDS at −2.1 in CGHD, −1.5
in TGHD, and −1.9 in MPHD.
Conclusions: Our findings indicate that the best cut-off for GH peak after retesting with
GHRHarg changes according to the etiology of GHD during the transition age. Based on
these results the diagnostic accuracy of GHRHarg remains questionable.
Keywords: GH deficiency, transition, GHRH-arg, young adults, brain tumors
INTRODUCTION
Growth hormone deficiency (GHD) is a well-recognized clinical
entity in adults. It is characterized by abnormalities in substrate
metabolism, body composition, physical, and psychosocial
functioning, all of which improve after GH replacement (1).
Likewise, there is evidence that in young patients with persistent
GHD full somatic maturation is not achieved if GH replacement
therapy is discontinued after final height achievement. It is
therefore recommended to evaluate the need to continuing GH
replacement after completion of growth (age between 15 and 25
years) (1).
The last international consensus statement (2), recommended
re-testing for GH secretion young adults with childhood-onset
GHD (COGHD) and evidence of hypothalamic-pituitary disease
for whom there is intention to treat. This includes patients (1)
with signs and symptoms of hypothalamic-pituitary disease from
endocrine, structural, and/or genetic causes; (2) who received
cranial irradiation or brain tumor treatment; and (3) who
presented traumatic brain injury or subarachnoid hemorrhage.
The consensus recommended to continue GH replacement
therapy, without the need for GH re-testing, in young adults
with a transcription factor mutation, in those with more than
three pituitary hormone deficits, and in those with isolated GHD
associated with an identified genetic mutation.
A cutoff value of <6.0 µg/L after insulin tolerance test
(ITT) was suggested to confirm the diagnosis of GHD during
the transition period (2). However, since this indication was
based on data obtained on a small cohort (3), further validation
was recommended (2). Some later studies confirmed that this
suggested cutoff was accurate to diagnose GHD in patients with
high likelihood of permanent GHD, i.e., those with COGHD and
structural hypothalamic-pituitary abnormalities (4, 5). Another
study suggested that this value might not be reliable for the
diagnosis of permanent GHD in the transition age (6). In a more
recent study performed in a larger cohort of COGHD, ROC
curve analysis indicated the best diagnostic accuracy for a GH
peak after ITT of 5.62 µg/liter (7) confirming that the GH peak
proposed by the Consensus was adequate for the definition of
permanent GHD in young adults with COGHD (2). Finally, a
systematic review from an Endocrine Society taskforce stated that
insufficient data are available to assess the accuracy of serial GH
testing in survivors of childhood cancers (8).
A number of studies have shown that patients with COGHD
may have normal GH secretion when re-evaluated at the end
of adult height achievement (4–7, 10). Therefore, re-testing for
GH secretion is recommended to confirm the diagnosis of GHD
in adolescents or young adults with COGHD. However, there is
still controversy about which limit for a normal response should
be considered in this age group. The ITT cut-off proposed by
the 2007 Consensus (2) was first established by our group in a
small cohort of 26 subjects with COGHD and high likelihood of
permanent GHD compared with 39 controls (3). The GH peak
of 6.1 µg/liter was the highest observed value in the patients
and the lowest in the controls, with 96% sensitivity and 100%
specificity (3).
ITT evaluates the integrity of the hypothalamic–pituitary axis,
but it is contraindicated in patients with ischemic heart disease or
seizures, and, thus, other testing modalities should be considered.
Combined GH-releasing hormone plus arginine (GHRHarg) has
been proposed as an alternative. We have previously shown that
the cut-off limit for the normal GH response after GHRHarg
was ≥19 µg/L (9), a value derived from a study performed in a
large cohort of patients with normal BMI, and high likelihood
of permanent GHD. Other studies, however, suggested that
GHRHarg could be unreliable in the diagnosis of children and
adults with COGHD (10, 11). A cut-off of <9 µg/L has been
proposed for adults with childhood cancer and brain irradiation
(12, 13), and a study by Darzy et al. (14) showed a high rate of
false negative diagnosis when GH secretion is explored early after
cranial irradiation. Since BMI has a strong negative influence on
the GH response to stimulation testing (15, 16), normal limits
for the GH response to GHRHarg corrected for BMI have also
been proposed in adult patients (17). The American Association
of Clinical Endocrinologist guidelines indicated that the BMI-
based cut-off limits were <11, <8, and <4 µg/L in adult patients
with BMI<25, between 25–30, and>30 kg/m2, respectively (17),
while BMI-based normal limits in young adults who achieved
final height are still lacking.
The aim of the study was to evaluate the reliability of
the GHRHarg testing in the diagnosis of permanent GHD in
COGHD based on (1) their GH response to ITT<6 µg/L (used
as the gold standard), (2) on the underlying etiology associated
with the presence of known risk factors for GHD (2), and (3)
the presence of isolated GHD or multiple pituitary hormone
deficiencies. To this end, we investigated in a multicenter study
a large cohort of patients who underwent ITT and GHRHarg
stimulation testing after achievement of adult height.
PATIENTS AND METHODS
Subjects
This is a multicenter cross-sectional study performed in 5
Italian Pediatric Endocrine Centers: Istituto Giannina Gaslini,
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Genova, Federico II University, Napoli, Ospedale Pediatrico
Bambino Gesù, Roma, Ospedale Pediatrico Microcitemico,
Cagliari. Subjects with COGHD who required GH treatment
during infancy-adolescence, aged 15–25 years and reached
pubertal maturity (Tanner stage 4–5) and adult height (defined as
a growth velocity below 2 cm in the previous year), were included
in the study.
Subjects with COGHD for whom ITT was contraindicated
(seizures or cardiac diseases) as well as patients who underwent
GHRHarg testing alone or with tests other than ITT were
excluded from the study. Based on the above criteria, 88 patients
(39 females, 49 males) among 129 eligible subjects were enrolled
in the analysis.
At the time of reassessment of GH secretory status, the
patients with idiopathic GHD (IGHD)with a GH response to ITT
at retesting ≥6 µg/L (2–5), normal MRI of the hypothalamic-
pituitary region and no other risk factors such as cranial or
craniospinal irradiation, were classified as a non-morbid control
group. In the statistical analysis, these subjects were considered
as true negatives. Patients with congenital abnormalities of
the hypothalamic-pituitary region (CGHD) [ectopic posterior
pituitary (EPP), n = 15], and those with CNS tumors or
previous cranial or craniospinal irradiation (tumoral GHD,
TGHD; n = 44) with peak GH to ITT <6 µg/L were considered
as true positives.
The diagnosis of GHD during childhood was based on the
well-recognized international criteria reported in other previous
studies (4–6). Mean age at diagnosis of idiopathic GHD (non-
morbid control group) was 7.9 ± 1.8 years, with a mean height
SDS of −2.4 ± 1.8 years and bone age of 5.7 ± 1.0 years;
mean age at diagnosis of CGHD was 4.2 ± 1.2 years, with a
mean height SDS of −3.0 ± 0.6 years and bone age of 2.5
± 0.5 years. Mean age at diagnosis of GHD in the 44 TGHD
patients was 10.8 ± 2.3 years, with a mean height SDS of
−1.9 ± 1.1 years and bone age of 8.3 ± 0.8 years; among the
32 irradiated patients, data on effective radiotherapy dose was
available in 29 TGHD patients. Pituitary dosimetry was estimated
on isodoses calculated at cranial radiotherapy (CRT) planning for
3 Dimensional conformational radiotherapy (RT-3D).
GHD diagnosis in childhood was established by a peak GH
response of less than 10 µg/liter after Arginine, ITT, glucagon or
clonidine tests based on the age at presentation or in the presence
of contraindications. All tests were performed between 08:00
and 09:00 after overnight fasting. Arginine was administered
intravenously (0.5 g/kg, max 30 g) during 30min and blood
samples for GH determination were collected at times −30,
0, 15, 30, 45, 60, 90, and 120min. Insulin was administered
intravenously (0.05–0.1 U/kg) and blood samples for GH and
glucose determinations were collected at times 0, 30, 60, 90,
and 120min. A nadir glucose value during ITT below 40 mg/dL
(2.2 mmol/L) was recorded in all subjects at time 30min. The
glucagon was administered im at the dose of 30mcg/kg glucagon
(maximum 1mg) and blood samples for GH, cortisol, and blood
glucose were collected at time 0 and at 60, 90, 120, 150, and
180min. Clonidine was administered orally (0.15 mg/m2) and
blood samples for GH determination were collected at times 0,
30, 60, 90, and 120min. Stimulation tests were performed on
separate days (at least 2 days apart). The diagnosis of GHD was
based on clinical characteristics and a peak GH <10 µg/L after
two stimulation tests.
According to the 2007 WHO classification of tumors
of the CNS (18), patients with brain tumors (n = 42)
included embryonal tumors (n = 23, 19 medulloblastoma, 2
Langerhans cell histiocytosis, 2 PNET), germ cell tumors (n
= 8, 6 germinoma), tumors of the sellar region (n = 4, all
craniopharyngioma), ependymal tumors (n = 2), astrocytic
tumors (n = 4 low grade glioma), mesenchymal tumors (n
= 1). The hematopoietic neoplasms (n = 2) included one
patient with acute lymphoblastic leukemia and one with acute
myeloid leukemia.
Fifty-four out of 88 patients had isolated GHD (iGHD)
whereas 34 had multiple pituitary hormone defects (MPHD).
Among the patients with MPHD, 26 had hypothyroidism, 19
had adrenal insufficiency, 15 had hypogonadism, and 11 had
diabetes insipidus. One, 2, 3, and 4 additional hormone deficits
were present in 14, 9, 5, and 6 patients, respectively. All patients
with MPHD were receiving conventional replacement therapy
with L-thyroxine (range 30–90 mcg/m2), hydrocortisone (7-
9 mg/m2/day), testosterone enanthate (250 mg/i.m./3 weeks),
ethinyl estradiol (up to 30 mcg/day for 21 days/month)
or transdermal 17β-estradiol patches (50 mcg/day for 21
days/month) withmedroxyprogesterone acetate for females (2.5–
10 mg/day for 11 days/month), and desmopressin acetate (range
30–120 mcg 3 times/day), as needed.
Methods
The study was approved by the Ethical Committee of Istituto
Giannina Gaslini and written informed consent was obtained
from the patients prior to the study (code IGG MOMA 003). All
patients included in the study were re-tested for GH secretion at
least 1 month after GH treatment discontinuation. Demographic
data (date of birth, primary diagnosis, date of primary diagnosis,
date of GHD diagnosis, date of last GH treatment, date of GH
re-testing) were recorded, and anthropometric measures (Height
SDS, BMI and BMI SDS) were obtained.
All patients underwent ITT and GHRHarg testing on separate
days as previously described (4, 5, 9–11). The tests were
performed after midnight fasting and omitting their morning
medications, with the exception of hydrocortisone in patients
with adrenal insufficiency. IGF-I concentrations were also
measured at baseline. All samples were collected, and centralized
at the laboratory of Istituto Giannina Gaslini, Genova and stored
at−80◦ until analyzed.
Assays
Serum GH was measured by chemiluminescent immunometric
assay (Immulite 2000, growth hormone; Diagnostic Products
Corporation, Los Angeles, CA; international reference
preparation 98/574). The inter- and intra-assay coefficients
of variation were 4.2–6.6 and 2.9–4.6%, respectively, at GH
concentrations of 2.6–17 µg/L. All samples from each individual
subject were analyzed together at the same time. Serum IGF-I
was measured by chemiluminescent immunometric assay
(Immulite 2000; Diagnostic Products Corporation). The intra-
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and inter-assay coefficients of variation were 3.4 and 7.1%,
respectively, and the sensitivity of the method was 2.6 nmol/L.
After centrifugation at 4 C, plasma was separated and stored
at 20C. Serum glucose was measured automatically with a
hexokinase catalyzed-glucose oxidase method.
Statistical Analysis
Patients’ characteristics were collected at the time of their
recruitment. Weight, height, target height and BMI were
converted in SDS based on Italian standards (19).
IGF-I-SDS was calculated using the normative data for the
analytical method described by Bidlingmaier et al. (20). Statistical
analyses were performed also based on the underlying etiology
such as CGHD, TGHD and based on the number of pituitary
defects i.e. isolated GHD or MPHD, independently of GH peak
response to ITT.
Descriptive statistics were reported as frequencies and
absolute numbers for qualitative variables. Quantitative variables
were non-normally distributed and were expressed as median
and interquartile range (IQRs) (the distance between the 25 and
75th percentile). Comparison of median values between different
categories was performed using the Mann-Whitney U test for
two-group comparisons, while the Kruskal-Wallis test was used
when comparing more than two groups.
The GH peak after ITT and GHRHarg and IGF-I SDS
were evaluated by standard non-parametric ROC curve analysis
(21). Different groups of GHD patients were considered: (1)
patients with congenital growth hormone deficiency (CGHD),
(2) tumoral GHD (TGHD), (3) isolated GHD, and (4) MPHD.
Sensitivity, specificity and global accuracy were evaluated at the
optimal ROC analysis cut-offs, corresponding to the highest value
of the Youden index (21).
ROC curves of the GH peak after GHRHarg adjusted for the
potential confounding effect of BMI and BMI SDSweremade and
analyzed by the method proposed by Janes et al. (22), which uses
the residuals from a linear regression model to remove the effect
of confounders (22). A P-value 0.05 was considered statistically
significant. All tests were two-sided. Statistical analyses were
performed using Stata for Windows statistical software (Stata
release 9.2; Stata Corporation, College Station, TX).
RESULTS
The characteristics of true positive patients and true negatives
subjects are reported in Table 1, while those of the entire cohort
based on their underlying etiologies (IGHD, CGHD, TGHD), and
on the presence of isolated GHD orMPHD, independently of GH
peak to ITT, are summarized in Table 2. The classification of the
entire cohort is reported in Figure 1.
All subjects reached a nadir blood glucose level during ITT
<2.2 mmol/liter (40 mg/dl). Based on the GH response to
ITT < or ≥6 µg/L, 29 patients with IGHD showed a GH
peak ≥6 µg/L (true negatives) and 11 CGHD and 31 TGHD
had a GH peak <6 µg/L (true positives). In particular, true
positives CGHD showed a GH peak to ITT significantly lower
compared to true positives TGHD (Table 1). Four out of 15
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44 TGHD (n = 8 isolated GHD, n = 5 MPHD) showed a
GH response to ITT ≥6 µg/L (Figure 1) despite the presence
of known risk factors for high likelihood GHD as defined
by the consensus (1), i.e. severe GHD in childhood with or
without two or three additional hormone deficits, possibly
due to a genetic abnormality, structural hypothalamic-pituitary
abnormalities, central nervous system tumors or after high-dose
cranial irradiation.
Median GH peak after ITT was significantly lower in CGHD
and TGHD patients than in IGHD subjects (Table 2).
GHRHarg Testing
Figure 2 shows the distribution of GH peak to GHRHarg based
on the ITT response < or ≥6 µg/L. Regarless of the underlying
etiology there was a wide overlap of GH values between 8.8 and
26.3 µg/L. Forty-six subjects [17 of whom with a high likelihood
GHD such as CGHD (n = 4), and TGHD (n = 13)], showed a
GH peak to ITT ≥6 µg/L and 42 <6 µg/L (true positive) with
a peak GH after GHRHarg ranging between 8.7–124 µg/L and
0.3–26.3 µg/L, respectively (Figure 2). In the true positive GHD
subjects GH peak responses to GHRHarg ranged between 0.3 and
26.3 µg/L; in particular, GH peak was lower in CGHD (median
3.1, range 0.3–22.5µg/L) compared to TGHD (median 8.1, range
0.6–26.3 µg/L) (Table 1).
The median GH response to GHRHarg in the entire cohort
based on their underlying etiology and the number of pituitary
defects is reported in Table 2 In particular, the GH response was
significantly lower in CGHD and TGHD patients than in IGHD
subjects and in MPHD patients compared to isolated GHD.
The results of ROC curve analysis of GHRHarg in patients
with CGHD (panel a), TGHD (panel b), and MPHD (panel c)
are reported in Figure 3. The highest proportion of correctly
classified CGHD patients (88.6%) was obtained for a GH peak
cutoff of 25.3 µg/liter (95% CI, 13.4–27.0; sensitivity, 93.3%, 95%
CI: 82.7–100%; specificity, 86.2%, 95%CI: 75.7–96.8%; AUC 0.93;
95% CI, 0.84–1.00). It was 82.1% in TGHD patients for a GH
peak of 15.7 µg/liter (95% CI, 15.6–38.7; sensitivity, 70.5%, 95%
CI: 59.2–81.8%; specificity, 100.0%; AUC 0.93; 95% CI, 0.87–
0.98), and of 80.7% in MPHD patients for a GH peak of 13.8
µg/liter (95% CI, 12.5–25.3; sensitivity, 79.4%, 95%CI: 68.0–
90.8%; specificity, 80.5%, 95% CI: 72.8–90.2%; AUC 0.84; 95%
CI, 0.76–0.92).
BMI and GH Response to GHRHarg
There was a significant inverse correlation between BMI SDS
and GH peak responses to GHRHarg (r = −0.43, p < 0.0001)
when considering the entire cohort; a similar correlation (r =
−0.43; p = 0.003) was found in TGHD patients. Based on these
findings ROC curves were adjusted for either BMI or BMI SDS,
showing that obesity could be a confounder (=lower peak) in
interpreting the GH response in obese patients with MPHD
(AUC 0.78 vs. 0.84; 95% CI, 0.67–0.89, and AUC 0.79 vs. 0.84;
95% CI, 0.68–0.89, respectively) (data not shown). A significant
inverse correlation between BMI SDS and GH peak response was
also found after ITT (r=−0.43, p < 0.0001) in the whole cohort
and in TGHD (r=−0.33; p= 0.03).
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FIGURE 1 | Classification of the patients based on peak GH response to ITT < or ≥6 µg/L, the underlying etiology; idiopathic GHD (IGHD), congenital GHD (CGHD),
tumoral GHD (TGHD), and the presence of isolated GHD (iGHD) or multiple pituitary hormone defects (MPHD).
FIGURE 2 | GH peak to GHRHarg in the cohort based on the GH response to
ITT ≥6 µg/L or <6 µg/L. The peak GH to GHRHarg values between 8.8 µg/L
(lowest peak in subjects with GH ≥ 6 µg/L) and 26.3 µg/L (highest peak in
patients with GH <6 µg/L) are represented; 29 subjects with idiopathic GHD
(open triangles), 15 with congenital GHD (closed squares), and 44 Tumoral
GHD (open circles).
IGF-I SDS
True positives CGHD had lower IGF-1 SDS (median−4.3, range
−8.1 to −1.1) compared to true positives TGHD (median −2.0,
range −7.1 to 1.8, p = 0.094) (Table 1). The median IGF-I SDS
in the entire cohort based on their underlying etiology and the
number of pituitary defects is reported in Table 2. Median IGF-I
SDS was significantly lower in CGHD and TGHD patients than
in IGHD subjects (−0.5; IQR,−1.1–0.4) (p < 0.0001).
Results of ROC analysis in patients with CGHD (Figure 3D),
TGHD (Figure 3E), and MPHD (Figure 3F) are reported in
Figure 3. IGF-I SDS showed the best diagnostic accuracy for
CGHD (85.7% correctly classified subjects) with an optimal
IGF-I SDS cutoff of−2.1 SDS (sensitivity, 60.0%, 95%CI: 39.3–
80.7%; specificity 100%; AUC 0.79; 95% CI, 0.61–0.97). The
best diagnostic accuracy was 68.6% in TGHD patients for an
IGF-I SDS of −1.5 SDS (sensitivity, 55.8%, 95%CI: 43.4–68.2%;
specificity 82.4%, 95%CI: 73.7–91.2%; AUC 0.73; 95% CI, 0.62–
0.84); and specificity 88.9%, 95%CI: 80.0– 98.8%; AUC 0.77; 95%
CI, 0.66–0.88), 72.9% in MPHD patients with an IGF-I SDS of
−1.9 SDS (sensitivity, 58.8%, 95%CI: 45.0–72.6%).
Cranial Radiotherapy and GH Responses
Anthropometric measures and GH responses to GHRHarg in
29 TGHD patients (n = 12 females) with effective pituitary
radiotherapy dose are reported in Table 3; tumor diagnosis
were medulloblastomas (n = 14), geminomas (n = 6),
craniopharyngioma (n = 2), low grade gliomas (n = 3), PNET
(n = 2), other (n = 2). Effective pituitary RT dose was inversely
but not significantly related to the GH response after GHRHarg
(Figure 4), with a similar negative trend between the GH
response and years after RT (Figure 4).
DISCUSSION
The GHRHarg test is one of the most powerful GH stimulation
tests (23–25) and, at odds with classical provocative testing,
shows less intra-individual variability (25). This test has been
proposed as a reliable alternative to the classical provocative
tests for the diagnosis of GHD (26), although robust normative
data for late adolescence and young adulthood have not been
Frontiers in Endocrinology | www.frontiersin.org 6 July 2019 | Volume 10 | Article 525
Patti et al. GHRHarg Retesting in Transition Age
FIGURE 3 | ROC curve analyses of peak GH after GHRHarg and IGF-I SDS in (A,D) patients with congenital growth hormone deficiency (CGHD, A,D), tumoral GHD
(B,E), and (C,F) multiple pituitary hormone deficiency (MPHD).
TABLE 3 | Clinical characteristics and GH responses to GHRHarg in 29 patients
with effective RT pituitary dose.
Age at re-assessment, years 17.2 (15.9 to 18.7)
Age at off therapy, years 9.8 (6.8 to 11.9)
GHRHArg (GH peak), µg/L 17.4 (6.9 to 40.0)
IGF-I SDS −1.1 (−2.5 to −0.2)
Height, SDS −1.1 (−2.0 to −0.3)
BMI SDS 0.9 (−0.2 to 1.6)
Effective pituitary RT dose, Gy 40.0 (35.3 to 45.8)
Years after RT, years 6.8 (5.3 to 9.7)
established. Previous studies have shown that testing with
GHRHarg distinguishes normal subjects from those with MPHD
and that it is as sensitive as ITT for the diagnosis of GHD in
adults and older adolescents (25). Indeed, our group showed
that some children and young adults with congenital GHD or
acquired GHD may have a “normal” GH response to GHRHarg
(10, 11) suggesting that GHRHarg testing may fail to recognize
all patients with permanent GHD.
The present study shows that the GH response to GHRHarg
in adolescents and young adults with congenital or tumoral
COGHDdoes not always confirm the results of ITT. In particular,
the GHRHarg-induced GH secretion showed marked differences
both in true positives patients and in those with different
underlying etiologies with a high likelihood of permanent GHD.
These findings strongly suggest that the same GH cut-off value
after GHRHarg is not appropriate for the diagnosis of permanent
GHD after adult height achievement in all patients with
COGHD. By adopting a GH value <8.8 µg/L after GHRHarg,
24 (57%) among our true positives GHD patients would have
been correctly identified, while 3 patients (27%) with CGHD
and 15 (48.4%) with TGHD would have been misdiagnosed.
Furthermore, our current finding in 4 CGHD or TGHD patients
(10%) of a GH peak>19.0µg/L (data not shown), are partially in
agreement with those of our previous study supporting that a cut-
off limit of 19.0 µg/L after GHRHarg is a reliable diagnostic test
in patients with COGHD (9). These discrepancies may be due to
the better definition of the subjects’ characteristics of the present
study which includes congenital GHD, as well as to the inclusion
of a large number of irradiated cancer survivors. In addition,
we are aware that GH measurement is strongly influenced by
the type of assay (27). In this regard, it should be pointed
out that in this study we used a monoclonal chemiluminescent
immunometric assay with reference preparation 98/574 as
recommended by the GRS consensus (2), and that the assay was
centralized, while an immunoradiometric method was used in
the previous study (9). The importance of the GH assay in the
definition of normal limits has been recently confirmed in a
study showing that a GH value <15.9 µg/liter after GHRHarg
obtained with a conversion factor of an in-house RIA assay (28)
was accurate for the definition of GHD at the time of retesting
in adolescents previously treated with GHD. Furthermore, there
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FIGURE 4 | Relationship between GH peak responses to GHRHarg and (A) effective radiotherapy dose, and (B) distance (years) after radiotherapy.
was a significant inverse correlation between BMI SDS and peak
GH responses to GHRHarg in the entire cohort as well as in
MPHD and cancer survivor patients suggesting that BMI may
be among the factors that influence the variability of the GH
response also to stimulation with GHRHarg (15, 16). In the
study of Dreismann et al. (28) patients with BMI between−1and
0 SDS showed higher GH peaks compared to those with BMI
>1 SDS. On the other hand, the suggested cut-off peak after
GHRHarg <19 µg/liter for the diagnosis of permanent GHD
of our previous study (9), was established in lean subjects (BMI
<25 kg/m2). Taken together these findings indicate the need of
establishing cut-off limits appropriate for overweight and obese
patients in/during the transition phase.
The recent Endocrine Society Clinical Practice Guideline
addresses the problem of abnormalities of hypothalamic–
pituitary functioning and growth disorders frequently observed
in childhood cancer survivors (29). Testing with ITT, GHRH
(with or without arginine), and glucagon has been recommended,
in this order, for the diagnosis of GHD in adult survivors of
childhood cancer (29), while no recommendations were provided
for the diagnosis of GHD after adult height achievement in
COGHD. In addition, a systematic review on the diagnosis
of GHD as a late effect of radiotherapy in survivors of
childhood cancer raises the question on how to interpret the GH
response after GHRHarg in patients with primary hypothalamic
dysfunction (8) with a recommendation against the use of GHRH
alone or in combination with arginine after hypothalamic–
pituitary axis radiation. Our study, the largest reported so far
in cancer survivors retested after adult height achievement
(8), confirms that patients with GHD and brain tumors have
significantly lower responses of GH after GHRHarg, although
some of them perform well above the recommended cut-offs (9–
11, 15–17).
ROC analysis of IGF-I showed the best diagnostic accuracy for
an IGF-I cut-off of ∼2 SDS in congenital GHD and in patients
withMPHD and of−1.45 SDS in tumoral GHDwith a sensitivity,
and specificity ranging from 46.6 to 100%. This suggests that
IGF-I SDS cut-offs may differ based on the underlying conditions
and the severity of GHD and that IGF-I SDS performs poorly in
cancer survivors. These findings support the recommendations
against relying the diagnosis of GHD solely on serum IGF-
I levels in patients exposed to hypothalamic–pituitary axis
radiotherapy (29).
Our results are representative of the impact of effective
radiation dose and length of follow-up (time elapsed since
irradiation) on the pattern of peak GH responses to GHRHarg
showing that effective pituitary RT dose was inversely although
not significantly related to GH response after GHRHarg. The
non-significant negative trend to GHRHarg and the time interval
after irradiation, indicates that somatotroph dysfunction is time-
dependent and progressive. Indeed, the absence of a significant
reduction of the GH response over time in our study compared to
that by Darzy et al. (14) appear to be very likely due to the longer
time of follow-up as well as to the higher biological effective dose
of RT used in their cohort.
Results of the present investigation should be evaluated
at the light of some inevitable limits. First, the variability
of the cut-offs obtained by ROC analysis was quite high, as
pointed out by the large confidence intervals of their estimates.
Second, the selection of the optimal cut-off makes results
comparable to those of previous investigations, but does not
take into account the potentially different costs of false positive
and false negative errors. Third, the accuracy measured at an
optimal cut-off could be overestimated. Further investigations
on large independent cohorts should be carried out to confirm
our results.
In conclusion, in spite of the above cited limits, our findings
indicate that ITT testing in young adults with childhood onset
GHD is reliable in different GHD conditions, whereas the
diagnostic accuracy of GHRHarg remains questionable in several
patients. The different GH cut-offs obtained by ROC analysis in
congenital GHD, isolated GHD, MPHD and in cancer survivors
make testing with GHRHarg poorly useful in clinical practice,
and suggest the need for establishing normal GH peak values
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during the transition age for every underlying condition. The
progressive time-dependent reduction of the GH response to
GHRHarg in cancer survivors makes the interpretation of the GH
secretory status a real challenge.
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